Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Clinical Pharmacology in Drug Development|November 15, 2019
Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and LamivudineTeodora Pene Dumitrescu, Kavita Peddiraju, Caifeng Fu, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2021
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy ParticipantsTeodora Pene Dumitrescu, Samit R Joshi, Jianfeng Xu, et al.
British Journal of Clinical Pharmacology|February 3, 2021
Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adultsTeodora Pene Dumitrescu, Samit R Joshi, Jianfeng Xu, et al.
BMC Chemical Biology|March 17, 2012
HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, HckTeodora Pene-Dumitrescu, Sherry T Shu, Thomas E Wales, et al.
British Journal of Clinical Pharmacology|August 24, 2021
Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy womenTeodora Pene Dumitrescu, Thomas J Greene, Samit R Joshi, et al.
Plos One|October 24, 2018
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trialJavier Morales-Ramirez, Johannes R Bogner, Jean-Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2022
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254Christoph D Spinner, Franco Felizarta, Giuliano Rizzardini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid TumorsTimothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Pageof 2